The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Blinded validation study of genomic predictions for survival following adjuvant sequential anthracycline-docetaxel chemotherapy with or without endocrine therapy.
W. F. Symmans
Consultant or Advisory Role - Nuvera Biosciences (U)
Stock Ownership - Nuvera Biosciences
F. Andre
No relevant relationships to disclose
M. C. Liu
Honoraria - Veridex
Research Funding - Veridex
J. Delacruz
No relevant relationships to disclose
F. Peintinger
No relevant relationships to disclose
S. Borstnar
No relevant relationships to disclose
H. Wang
No relevant relationships to disclose
P. Regitnig
No relevant relationships to disclose
M. Ota
No relevant relationships to disclose
S. Seevaratnam
No relevant relationships to disclose
S. Delaloge
No relevant relationships to disclose
C. Hatzis
Employment or Leadership Position - Nuvera Biosciences
Stock Ownership - Nuvera Biosciences